EP1037627B1 - Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization - Google Patents
Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization Download PDFInfo
- Publication number
- EP1037627B1 EP1037627B1 EP99928600A EP99928600A EP1037627B1 EP 1037627 B1 EP1037627 B1 EP 1037627B1 EP 99928600 A EP99928600 A EP 99928600A EP 99928600 A EP99928600 A EP 99928600A EP 1037627 B1 EP1037627 B1 EP 1037627B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dihydrodibenz
- oxepin
- dimethylaminopropylidene
- acetic acid
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the therapeutic and prophylactic use of 11-(3-dimethylamino-propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for the administration to the for treating and/or preventing cytokine release from human ocular cells and resulting ocular neovascularization or non-allergic inflammatory conditions.
- the Kyowa patent demonstrates anti-allergic activity and anti-inflammatory activity in Wistar male rats.
- Medicament forms taught by the Kyowa patent for the acetic acid derivatives of doxepin include a wide range of acceptable carriers; however, only oral and injection administration forms are mentioned. In the treatment of allergic eye disease, such as allergic conjunctivitis, such administration methods require large doses of medicine.
- U.S. Patent No. 5,641,805 discloses topical ophthalmic formulations containing 11-(3-dimethylamino-propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for treating allergic eye diseases.
- the present invention provides the use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [b,e] oxepin-2-acetic acid (referred to as "Compound A” hereinafter) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for administration to the eye for treating or preventing ophthalmic neovascularization and non-allergic inflammatory disorders involving cytokine release from human ocular cells.
- Compound A 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [b,e] oxepin-2-acetic acid
- the formulation may contain the cis isomer of Compound A (Z-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz-[b,e]oxepin-2-acetic acid), the trans isomer of Compound A (E-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid), or a combination of both the cis and the trans isomers of Compound A.
- Compound A is a known compound and both the cis and the trans isomers of Compound A can be obtained by the methods disclosed in U.S. Patent No. 5,116,863,
- Examples of the pharmaceutically acceptable salts of Compound A include inorganic acid salts such as hydrochloride, hydrobromide, sulfate and phosphate; organic acid salts such as acetate, maleate, fumarate, tartrate and citrate; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; metal salts such as aluminum salt and zinc salt; and organic amine addition salts such as triethylamine addition salt (also known as tromethamine), morpholine addition salt and piperidine addition salt.
- inorganic acid salts such as hydrochloride, hydrobromide, sulfate and phosphate
- organic acid salts such as acetate, maleate, fumarate, tartrate and citrate
- alkali metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as magnesium salt and calcium salt
- metal salts such as aluminum salt and zinc salt
- organic amine addition salts such as triethy
- Compound A may be administered to the eye in a variety of ways. The most preferred way is by means of conventional topical ophthalmic formulations, such as solutions, suspensions or gels. Alternatively, Compound A may be administered to the eye via injection or implant. Depending upon the type of formulation, conventional ingredients will be combined with Compound A.
- the preferred formulation for topical ophthalmic administration of Compound A is a solution administered as eye drops.
- the preferred form of Compound A in the ophthalmic formulations of the present invention is the cis isomer.
- a general method of preparing an eye drop formulation of the present invention is described below as a nonlimiting example.
- Compound A and an isotonic agent are added to sterilized purified water, and if required, a preservative, a buffering agent, a stabilizer, a viscous vehicle and the like are added to the solution and dissolved therein.
- concentration of Compound A is 0.0001 to 5 w/v %, preferably 0.0001 to 0.001 w/v %, and most preferably 0.0005 w/v %, based on the sterilized purified water.
- the pH is adjusted with a pH controller to be within a range suitable for use as an ophthalmic medicine, preferably within the range of 4.5 to 8.
- Sodium chloride, glycerin, mannitol or the like may be used as the isotonic agent; p-hydroxybenzoic acid ester, benzalkonium chloride or the like as the preservative; sodium hydrogenphosphate, sodium dihydrogenphosphate, boric acid or the like as the buffering agent; sodium edetate or the like as the stabilizer; polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acid or the like as the viscous vehicle; and sodium hydroxide, hydrochloric acid or the like as the pH controller.
- ophthalmic drugs such as epinephrine, naphazoline hydrochloride, berberine chloride, sodium azulenesulfonate, lysozyme chloride, glycyrrhizate and the like may be added.
- the eye drops produced by the above method typically need only be applied to the eyes a few times a day in an amount of one to several drops at a time, though in more severe cases the drops may be applied several times a day.
- a typical drop is about 30 ⁇ l.
- ophthalmic formulations containing Compound A are used to inhibit pro-inflammatory cytokine secretion from human ocular cells, such as human conjunctival epithelial cells.
- This type of cytokine secretion e.g., IL-6 and IL-8
- IL-6 and IL-8 can stimulate ocular neovascularization (see, for example, Yoshida et al., IOVS, 39:1097 (1998)) and other non-allergic inflammatory conditions, such as dry eye, keratitits, blepharitis, uveitis and inflammation related to infection, for example.
- Example 1 Preferred Topical Ophthalmic Solution Formulation
- HCE Human Conjunctival Epithelial Cell
- cytokines IL-6 and IL-8
- IL-6 and IL-8 cytokines
- IL-6 and IL-8 were analyzed for IL-6 and IL-8 by ELISA (R&D Systems, Minneapolis, MN) as directed by the manufacturer.
- the sensitivities of each ELISA are as follows: IL-6 0.7 pg/ml and IL-8 3.0 pg/ml.
- the antagonist potency was defined as the concentration of the drug required to produce 50% inhibition of the agonist-stimulated functional response.
- Data derived from the cytokine assays were calculated as mean and standard error (SEM) values which represent the variability among identically treated culture wells.
- SEM standard error
- the dose-dependent effect of pharmacological agents and IC 50 's were determined by linear regression. Data are expressed as mean ⁇ S.E.M. from 3 - 5 independent experiments.
- the potency of emedastine in intact cells is consistent with its activity determined in receptor binding assays using tissue homogenates.
- Levocabastine also inhibited the IL-6, and IL-8 secretion at a level consistent with its H 1 -receptor binding affinity.
- Antazoline and pheniramine two first generation topical ocular anti-histamine compounds, were dramatically less potent inhibitors of IL-6 and IL-8 secretion than predicted from their histamine H 1 -receptor binding affinities (20 - 140-fold).
- Olopatadine was more potent than predicted from its published histamine H 1 -receptor binding affinity (36 nM).
- Histamine H 1 Antagonists Inhibition of IL-6 and IL-8 Secretion in Human Conjunctival Epithelial Cells and H 1 Receptor Binding Affinities H 1 Antagonist IL-6 IC 50 (nM) IL-8 IC 50 (nM) H 1 Binding K i (nM) Emedastine 2.5 4.0 1.22 Olopatadine 5.5 1.7 36.0 Levocabastine 25.1 11.9 52.6 Antazoline 1014 652 38.4 Pheniramine 4826 1216 33.9
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Ingredient | Concentration (W/V%) |
Compound A•HCl | 0.111 |
Dibasic Sodium Phosphate (Anhydrous), USP | 0.5 |
Sodium Chloride, USP | 0.65 |
Benzalkonium Chloride | 0.01 |
Sodium Hydroxide, NF 7.0 | q.s. pH = |
Hydrochloric Acid, NF 7.0 | q.s. pH = |
Purified Water | q.s. 100 |
Ingredient | Concentration (W/V%) |
Compound A•HCl | 0.11 |
Carbopol 974 P | 0.8 |
Disodium EDTA | 0.01 |
Polysorbate 80 | 0.05 |
Benzalkonium Chloride, Solution | 0.01+5 xs |
Sodium Hydroxide | q.s. pH 7.2 |
Hydrochloric acid | q.s. pH 7.2 |
Water for Injection | q.s. 100 |
Histamine H1 Antagonists: Inhibition of IL-6 and IL-8 Secretion in Human Conjunctival Epithelial Cells and H1 Receptor Binding Affinities | |||
H1 Antagonist | IL-6 IC50 (nM) | IL-8 IC50 (nM) | H1 Binding Ki (nM) |
Emedastine | 2.5 | 4.0 | 1.22 |
Olopatadine | 5.5 | 1.7 | 36.0 |
Levocabastine | 25.1 | 11.9 | 52.6 |
Antazoline | 1014 | 652 | 38.4 |
Pheniramine | 4826 | 1216 | 33.9 |
Claims (14)
- Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the administration to the eye for treating or preventing ocular neovascularization and non-allergic ophthalmic inflammatory disorders involving cytokine release from human ocular cells.
- Use of Claim 1 wherein the medicament is a topically administrable solution and the amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from 0.0001 w/v.% to 5% (w/v).
- Use of Claim 2 wherein the amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from 0.0001 to 0.001 % (w/v).
- Use of Claim 3 wherein the amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is 0.0005% (w/v).
- Use of Claim 1 wherein the 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is (Z)-11 -(3-dimethylaminopropylidene)-6,11 -dihydrodibenz[b,e]oxepin-2-acetic acid, substantially free of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid.
- Use of Claim 5 wherein the composition is a topically administrable solution and the amount of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from 0.0001 to 5% (w/v).
- Use of Claim 6 wherein the amount of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from 0.0001 to 0.001 % (w/v).
- Use of Claim 7 wherein the amount of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is 0.0005% (w/v).
- Use of Claim 1 wherein the 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, substantially free of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid.
- Use of Claim 9 wherein the composition is a topically administrable composition and the amount of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from 0.0001 to 5% (w/v).
- Use of Claim 10 wherein the amount of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from 0.0001 to 0.001% (w/v).
- Use of Claim 11 wherein the amount of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is 0.0005% (w/v).
- Use of Claim 1 wherein the non-allergic ophthalmic inflammatory disorder is selected from the group consisting of dry eye, keratitits, blepharitis, uveitis and inflammation related to infection.
- Use of Claim 1 wherein the ocular neovascularization and non-allergic ophthalmic inflammatory disorders involve cytokine release from human conjunctival epithelial cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9276298P | 1998-07-14 | 1998-07-14 | |
US92762P | 1998-07-14 | ||
PCT/US1999/013275 WO2000003705A1 (en) | 1998-07-14 | 1999-06-15 | Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1037627A1 EP1037627A1 (en) | 2000-09-27 |
EP1037627B1 true EP1037627B1 (en) | 2001-08-01 |
Family
ID=22235027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99928600A Expired - Lifetime EP1037627B1 (en) | 1998-07-14 | 1999-06-15 | Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1037627B1 (en) |
JP (1) | JP2002520355A (en) |
KR (1) | KR100598723B1 (en) |
CN (1) | CN1114401C (en) |
AR (1) | AR019916A1 (en) |
AT (1) | ATE203668T1 (en) |
AU (1) | AU742237B2 (en) |
BR (1) | BR9906772A (en) |
CA (1) | CA2306393C (en) |
DE (1) | DE69900207T2 (en) |
DK (1) | DK1037627T3 (en) |
ES (1) | ES2159209T3 (en) |
GR (1) | GR3036422T3 (en) |
HK (1) | HK1030362A1 (en) |
PT (1) | PT1037627E (en) |
TW (1) | TW561046B (en) |
WO (1) | WO2000003705A1 (en) |
ZA (1) | ZA200001593B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU770975B2 (en) | 1999-06-18 | 2004-03-11 | Alcon Laboratories, Inc. | Topical ophthalmic mast cell stabilizers for treating allergic eye diseases |
WO2002034246A2 (en) * | 2000-10-23 | 2002-05-02 | Alcon, Inc. | Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery |
US7112588B2 (en) | 2001-05-21 | 2006-09-26 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
BR0209883A (en) | 2001-05-21 | 2004-06-08 | Alcon Inc | Use of proteasome inhibitors for the treatment of dry eye disorders |
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
BR0209965A (en) * | 2001-05-21 | 2004-04-06 | Alcon Inc | Use of nf-kappab inhibitors to treat dry eye disorders |
US6645994B1 (en) | 2001-06-01 | 2003-11-11 | Alcon, Inc. | Method of treating dry eye disorders |
US7977376B2 (en) | 2001-06-27 | 2011-07-12 | Novartis Ag | Olopatadine formulations for topical nasal administration |
TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
US6825232B2 (en) | 2002-06-14 | 2004-11-30 | Alcon, Inc. | Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders |
WO2004010894A2 (en) | 2002-07-30 | 2004-02-05 | Omeros Corporation | Ophthalmologic irrigation solutions and method |
MXPA05003063A (en) | 2002-09-20 | 2005-05-27 | Alcon Inc | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders. |
WO2004093878A1 (en) * | 2003-04-16 | 2004-11-04 | Alcon, Inc. | Use of fused pyridazine derivatives for treating dry eye disorders |
US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
US7923471B2 (en) | 2004-05-14 | 2011-04-12 | Alcon, Inc. | Method of treating dry eye disorders and uveitis |
WO2006014434A2 (en) | 2004-07-02 | 2006-02-09 | Eliot Lazar | Treatment medium delivery device and methods for delivery |
US7223737B1 (en) | 2004-08-13 | 2007-05-29 | Alcon, Inc. | Method of treating dry eye disorders using glycosides |
DK1881823T3 (en) * | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS |
US7745461B1 (en) | 2006-02-27 | 2010-06-29 | Alcon Research, Ltd. | Method of treating dry eye disorders |
KR20140083056A (en) | 2006-03-17 | 2014-07-03 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | Stabilized ophthalmic compositions comprising oxidatively unstable components |
CN103393496B (en) | 2006-03-31 | 2016-08-17 | 玛提治疗有限公司 | Nasolachrymal drainage system implants for Drug therapy |
WO2009035571A2 (en) | 2007-09-07 | 2009-03-19 | Qlt Plug Delivery, Inc | Lacrimal implant detection |
US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
JP2013510095A (en) | 2009-11-06 | 2013-03-21 | アルコン リサーチ, リミテッド | Nutritional supplements to reduce dry eye |
AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
TWI705812B (en) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions |
CN109311976A (en) | 2016-06-20 | 2019-02-05 | 诺华股份有限公司 | Use the method for TNF α antagonist treatment xerophthalmia |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6310784A (en) * | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | Dibenz(b,e)oxepin derivative, antiallergic agent and anti-inflammatory agent |
JPH02138215A (en) * | 1988-08-05 | 1990-05-28 | Dai Ichi Seiyaku Co Ltd | Antiallergic and anti-inflammatory agent |
IE920499A1 (en) * | 1991-02-21 | 1992-08-26 | Merck Frosst Canada Inc | Quinoline-containing ketoacids as leukotriene antagonists |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
JP3453152B2 (en) * | 1992-04-06 | 2003-10-06 | 格 冨山 | Anti-inflammatory eye drops |
FR2701948B1 (en) * | 1993-02-22 | 1996-07-26 | Exsymol Sa | Coupling product of histamine or methyl-substituted histamine and an amino acid, process for preparation and therapeutic, cosmetic and food applications. |
ATE241359T1 (en) * | 1993-03-26 | 2003-06-15 | Beth Israel Hospital | TOPICAL AND SYSTEMIC USE OF BUSPIRON AND ITS DERIVATIVES FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH IMMUNE RESPONSES |
FR2711990B1 (en) * | 1993-11-05 | 1995-12-08 | Exsymol Sa | Pseudodipeptide product having an imidazole group, and therapeutic, cosmetological and agrifood applications. |
JP2852607B2 (en) * | 1994-06-10 | 1999-02-03 | 雪印乳業株式会社 | Dry eye treatment |
US5641805A (en) * | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
JPH1067684A (en) * | 1996-06-17 | 1998-03-10 | Mitsubishi Chem Corp | Accelerator of secretion of lacrimal fluid |
WO1998022130A1 (en) * | 1996-11-19 | 1998-05-28 | The Schepens Eye Research Institute, Inc. | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
-
1999
- 1999-06-15 BR BR9906772-2A patent/BR9906772A/en not_active Application Discontinuation
- 1999-06-15 ES ES99928600T patent/ES2159209T3/en not_active Expired - Lifetime
- 1999-06-15 JP JP2000559840A patent/JP2002520355A/en not_active Withdrawn
- 1999-06-15 EP EP99928600A patent/EP1037627B1/en not_active Expired - Lifetime
- 1999-06-15 AU AU45634/99A patent/AU742237B2/en not_active Ceased
- 1999-06-15 WO PCT/US1999/013275 patent/WO2000003705A1/en active IP Right Grant
- 1999-06-15 AT AT99928600T patent/ATE203668T1/en active
- 1999-06-15 DK DK99928600T patent/DK1037627T3/en active
- 1999-06-15 CN CN99801501A patent/CN1114401C/en not_active Expired - Fee Related
- 1999-06-15 PT PT81300632T patent/PT1037627E/en unknown
- 1999-06-15 CA CA002306393A patent/CA2306393C/en not_active Expired - Fee Related
- 1999-06-15 DE DE69900207T patent/DE69900207T2/en not_active Expired - Lifetime
- 1999-06-15 KR KR1020007004037A patent/KR100598723B1/en not_active IP Right Cessation
- 1999-06-25 TW TW088110742A patent/TW561046B/en not_active IP Right Cessation
- 1999-07-13 AR ARP990103415A patent/AR019916A1/en unknown
-
2000
- 2000-03-29 ZA ZA200001593A patent/ZA200001593B/en unknown
-
2001
- 2001-02-14 HK HK01101081A patent/HK1030362A1/en not_active IP Right Cessation
- 2001-08-20 GR GR20010401273T patent/GR3036422T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT1037627E (en) | 2001-11-30 |
CA2306393A1 (en) | 2000-01-27 |
DE69900207D1 (en) | 2001-09-06 |
KR100598723B1 (en) | 2006-07-11 |
AR019916A1 (en) | 2002-03-27 |
BR9906772A (en) | 2000-09-26 |
KR20010024508A (en) | 2001-03-26 |
AU4563499A (en) | 2000-02-07 |
EP1037627A1 (en) | 2000-09-27 |
CA2306393C (en) | 2008-12-23 |
JP2002520355A (en) | 2002-07-09 |
CN1114401C (en) | 2003-07-16 |
ATE203668T1 (en) | 2001-08-15 |
CN1275078A (en) | 2000-11-29 |
ES2159209T3 (en) | 2001-09-16 |
HK1030362A1 (en) | 2001-05-04 |
ZA200001593B (en) | 2000-10-25 |
AU742237B2 (en) | 2001-12-20 |
GR3036422T3 (en) | 2001-11-30 |
DK1037627T3 (en) | 2001-10-01 |
TW561046B (en) | 2003-11-11 |
WO2000003705A1 (en) | 2000-01-27 |
DE69900207T2 (en) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1037627B1 (en) | Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization | |
EP0799044B1 (en) | Topical ophthalmic formulations containing olopatadine for treating allergic eye diseases | |
EP1679074B1 (en) | Therapeutic agent for keratoconjunctive disorder | |
US20080139531A1 (en) | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair | |
US20060014786A1 (en) | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
US7084157B2 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
AU4610101A (en) | Use of H1 antagonist and a safe steroid to treat eye conditions | |
US20180021314A1 (en) | Therapeutic agent for meibomian dysfunction | |
EP0634932B1 (en) | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists | |
US6225327B1 (en) | Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications | |
JP2001508035A (en) | Ophthalmic composition containing carbonic anhydrase inhibitor and xanthan gum | |
US6174914B1 (en) | Method of inhibiting cytokine release from human ocular cells | |
US20050009902A1 (en) | Remedies for pruritus | |
HUE026162T2 (en) | Olopatadine formulations for topical nasal administration | |
MXPA00004061A (en) | Use of 11-(3-dimethylaminopropylidene)- 6,1 -dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization | |
JP3662944B2 (en) | Nasal drops | |
US7910575B2 (en) | Prophylactic or therapeutic agents for allergic ophthalmic diseases or allergic nasal diseases, comprising tricyclic triazolobenzazepine derivative | |
JP2852607B2 (en) | Dry eye treatment | |
US20090270474A1 (en) | Therapeutic Agent for Keratoconjunctival Disorder | |
WO1998056379A1 (en) | Compositions and methods for treating glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000406 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 20001025 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REF | Corresponds to: |
Ref document number: 203668 Country of ref document: AT Date of ref document: 20010815 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69900207 Country of ref document: DE Date of ref document: 20010906 |
|
ITF | It: translation for a ep patent filed |
Owner name: ST. DR. CAVATTONI ING. A. RAIMONDI |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2159209 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20010830 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: KYOWA HAKKO KOGYO CO., LTD. Free format text: ALCON LABORATORIES, INC.#R & D COUNSEL Q-148, 6201 SOUTH FREEWAY#FORT WORTH, TEXAS 76134-2099 (US) -TRANSFER TO- KYOWA HAKKO KOGYO CO., LTD.#6-1, OHTEMACHI 1-CHOME#CHIYODA-KU, TOKYO 100 (JP) $ ALCON MANUFACTURING LTD.#6201 SOUTH FREEWAY#FORT WORTH, TEXAS 76134-2099 (US) |
|
NLS | Nl: assignments of ep-patents |
Owner name: KYOWA HAKKO KOGYO CO., LTD Owner name: ALCON MANUFACTURING LTD. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Free format text: ALCON MANUFACTURING LTD. US Effective date: 20040702 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20160609 Year of fee payment: 18 Ref country code: ES Payment date: 20160511 Year of fee payment: 18 Ref country code: CH Payment date: 20160613 Year of fee payment: 18 Ref country code: DE Payment date: 20160607 Year of fee payment: 18 Ref country code: IE Payment date: 20160609 Year of fee payment: 18 Ref country code: GB Payment date: 20160615 Year of fee payment: 18 Ref country code: LU Payment date: 20160607 Year of fee payment: 18 Ref country code: GR Payment date: 20160516 Year of fee payment: 18 Ref country code: MC Payment date: 20160426 Year of fee payment: 18 Ref country code: CY Payment date: 20160511 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20160516 Year of fee payment: 18 Ref country code: PT Payment date: 20160614 Year of fee payment: 18 Ref country code: BE Payment date: 20160425 Year of fee payment: 18 Ref country code: DK Payment date: 20160610 Year of fee payment: 18 Ref country code: SE Payment date: 20160613 Year of fee payment: 18 Ref country code: NL Payment date: 20160610 Year of fee payment: 18 Ref country code: AT Payment date: 20160525 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20160621 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69900207 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20170630 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20170701 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 203668 Country of ref document: AT Kind code of ref document: T Effective date: 20170615 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20170615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170616 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180103 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180111 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170615 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20170630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20181106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170616 |